Celia Hart represents Supernova Invest on the board of Keranova. She has more than 20 years of experience in the chemical and biotechnology sector. Following her chemistry Ph.D. at Oxford University (UK), Celia worked for Cambridge Antibody Technology, UK (now MedImmune) holding different positions including Head of Lead Optimization.
She was involved in the development of several therapeutic antibodies in collaboration with international biotechnology and pharmaceutical partners.
In France, she assessed new business opportunities for the European Synchrotron Radiation Facility (ESRF) and the Atomic Energy Commission (CEA). She joined CEA Investissement (now Supernova Invest) in 2005 and is currently General Partner. She serves (or has served) on the Boards of several companies including Algaia, Carthéra, Diabeloop, NH Theraguix, Theranexus and Uromems.
Celia holds a degree in Chemistry from the University of Geneva (Switzerland), a Ph.D. from Oxford University (UK) and an MBA from Grenoble École de Management (France).